Cargando…
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden in interferon-treated patients, but significance of this observation is question...
Autores principales: | Verger, Emmanuelle, Soret-Dulphy, Juliette, Maslah, Nabih, Roy, Lydia, Rey, Jerome, Ghrieb, Zineb, Kralovics, Robert, Gisslinger, Heinz, Grohmann-Izay, Barbara, Klade, Christoph, Chomienne, Christine, Giraudier, Stéphane, Cassinat, Bruno, Kiladjian, Jean-Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172224/ https://www.ncbi.nlm.nih.gov/pubmed/30287855 http://dx.doi.org/10.1038/s41408-018-0133-0 |
Ejemplares similares
-
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2022) -
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
por: Gisslinger, Heinz, et al.
Publicado: (2023) -
CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020) -
Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements
por: Drevon, Louis, et al.
Publicado: (2021) -
JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
por: Dagher, Tracy, et al.
Publicado: (2020)